Cargando…
The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy
SIMPLE SUMMARY: In this review article, we highlight the process and importance of identifying neoantigens for immunotherapy for cancer. Although the process of identifying neoantigens may be time-consuming and costly, various efforts are being conducted at different stages of pre-clinical and clini...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454936/ https://www.ncbi.nlm.nih.gov/pubmed/36077792 http://dx.doi.org/10.3390/cancers14174255 |
_version_ | 1784785469651812352 |
---|---|
author | Kye, Yae Nagineni, Lokesh Gadad, Shrikanth Ramirez, Fabiola Riva, Hannah Fernandez, Lorena Samaniego, Michelle Holland, Nathan Yeh, Rose Takigawa, Kei Dhandayuthapani, Subramanian Chacon, Jessica |
author_facet | Kye, Yae Nagineni, Lokesh Gadad, Shrikanth Ramirez, Fabiola Riva, Hannah Fernandez, Lorena Samaniego, Michelle Holland, Nathan Yeh, Rose Takigawa, Kei Dhandayuthapani, Subramanian Chacon, Jessica |
author_sort | Kye, Yae |
collection | PubMed |
description | SIMPLE SUMMARY: In this review article, we highlight the process and importance of identifying neoantigens for immunotherapy for cancer. Although the process of identifying neoantigens may be time-consuming and costly, various efforts are being conducted at different stages of pre-clinical and clinical development to improve the process and identify neoantigens. This initiative will be imperative in developing the next generation of cost-efficient and potent immunotherapies against cancer. ABSTRACT: The era of personalized cancer therapy is here. Advances in the field of immunotherapy have paved the way for the development of individualized neoantigen-based therapies that can translate into favorable treatment outcomes and fewer side effects for patients. Addressing challenges related to the identification, access, and clinical application of neoantigens is critical to accelerating the development of individualized immunotherapy for cancer patients. |
format | Online Article Text |
id | pubmed-9454936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94549362022-09-09 The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy Kye, Yae Nagineni, Lokesh Gadad, Shrikanth Ramirez, Fabiola Riva, Hannah Fernandez, Lorena Samaniego, Michelle Holland, Nathan Yeh, Rose Takigawa, Kei Dhandayuthapani, Subramanian Chacon, Jessica Cancers (Basel) Review SIMPLE SUMMARY: In this review article, we highlight the process and importance of identifying neoantigens for immunotherapy for cancer. Although the process of identifying neoantigens may be time-consuming and costly, various efforts are being conducted at different stages of pre-clinical and clinical development to improve the process and identify neoantigens. This initiative will be imperative in developing the next generation of cost-efficient and potent immunotherapies against cancer. ABSTRACT: The era of personalized cancer therapy is here. Advances in the field of immunotherapy have paved the way for the development of individualized neoantigen-based therapies that can translate into favorable treatment outcomes and fewer side effects for patients. Addressing challenges related to the identification, access, and clinical application of neoantigens is critical to accelerating the development of individualized immunotherapy for cancer patients. MDPI 2022-08-31 /pmc/articles/PMC9454936/ /pubmed/36077792 http://dx.doi.org/10.3390/cancers14174255 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kye, Yae Nagineni, Lokesh Gadad, Shrikanth Ramirez, Fabiola Riva, Hannah Fernandez, Lorena Samaniego, Michelle Holland, Nathan Yeh, Rose Takigawa, Kei Dhandayuthapani, Subramanian Chacon, Jessica The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy |
title | The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy |
title_full | The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy |
title_fullStr | The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy |
title_full_unstemmed | The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy |
title_short | The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy |
title_sort | identification and clinical applications of mutated antigens in the era of immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454936/ https://www.ncbi.nlm.nih.gov/pubmed/36077792 http://dx.doi.org/10.3390/cancers14174255 |
work_keys_str_mv | AT kyeyae theidentificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT naginenilokesh theidentificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT gadadshrikanth theidentificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT ramirezfabiola theidentificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT rivahannah theidentificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT fernandezlorena theidentificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT samaniegomichelle theidentificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT hollandnathan theidentificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT yehrose theidentificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT takigawakei theidentificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT dhandayuthapanisubramanian theidentificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT chaconjessica theidentificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT kyeyae identificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT naginenilokesh identificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT gadadshrikanth identificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT ramirezfabiola identificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT rivahannah identificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT fernandezlorena identificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT samaniegomichelle identificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT hollandnathan identificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT yehrose identificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT takigawakei identificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT dhandayuthapanisubramanian identificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy AT chaconjessica identificationandclinicalapplicationsofmutatedantigensintheeraofimmunotherapy |